TP53 and ovarian cancer: However, while the combined inhibition of both AURK and Chk has been shown to induce synthetic lethality in ovarian cancer [17], a type of cancer characterized by frequent TP53 mutations, this strategy has not been evaluated in TP53 mutant AML.